Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Community-acquired pneumonia,Acute bacterial sinusitis,Acute bacterial exacerbation of chronic bronchitis,Skin and skin structure infections (uncomplicated and complicated),Complicated intra-abdominal infections,Pelvic inflammatory disease,Urinary tract infections (complicated and uncomplicated),Prophylaxis of anthrax exposure,Plague,Empiric therapy in febrile neutropenia (off-label)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
400 mg intravenously once daily.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
12-15 hours (terminal elimination half-life; allows once-daily dosing; may be prolonged in renal impairment).
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Moxifloxacin undergoes sulfate conjugation (phase II metabolism) via sulfotransferases; it is not metabolized by cytochrome P450 enzymes. Approximately 20% is excreted unchanged in urine, and 25% as a glucuronide conjugate.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal (~20% unchanged, plus ~35% as glucuronide and sulfate conjugates), biliary/fecal (~25% unchanged and conjugates, total ~50% via feces).
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
~50% bound, primarily to serum albumin.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
2.5–3.5 L/kg (indicates extensive tissue penetration, including lung and sinuses).
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Oral: ~90% (bioequivalent to IV).
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No dose adjustment required for GFR ≥30 m L/min; insufficient data for GFR <30 m L/min, use with caution.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No dose adjustment for Child-Pugh A or B; not recommended for Child-Pugh C due to lack of data.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Not recommended for patients <18 years due to risk of musculoskeletal adverse effects.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
No specific dose adjustment; monitor for QT prolongation and tendon effects.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Fluoroquinolones, including moxifloxacin, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in patients over 60 years of age, in those taking corticosteroids, and in kidney, heart, or lung transplant recipients. Fluoroquinolones may exacerbate muscle weakness in patients with myasthenia gravis. Avoid use in patients with known myasthenia gravis.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Tendon injury (tendinitis, tendon rupture),Worsening of myasthenia gravis,Peripheral neuropathy, irreversible,Central nervous system effects (seizures, dizziness, confusion),QT prolongation (avoid in patients with known QTc prolongation, electrolyte abnormalities, or concomitant QT-prolonging drugs),Hypersensitivity/anaphylactic reactions,Clostridioides difficile-associated diarrhea,Photosensitivity/phototoxicity,Blood glucose disturbances (especially in diabetic patients on oral hypoglycemics or insulin),Avoid in patients with known aortic aneurysm or at risk for aortic aneurysm
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Known hypersensitivity to moxifloxacin or any fluoroquinolone,Pregnancy (animal data showing fetal harm; avoid unless benefit outweighs risk),Lactation (not recommended; may cause articular damage in nursing infants),Patients under 18 years of age (except for specific approved indications like anthrax),History of tendon disorders related to fluoroquinolone use,Uncorrected hypokalemia or hypomagnesemia (risk of QTc prolongation),Concomitant use with Class IA or Class III antiarrhythmics (QT prolongation risk)
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Avoid concurrent intake of dairy products (milk, yogurt, cheese), antacids containing calcium, magnesium, or aluminum, and supplements with calcium, iron, or zinc. Separate dosing by at least 2 hours before or 6 hours after these products. Caffeine intake should be limited as moxifloxacin may increase its effects (nervousness, insomnia). No other significant food interactions.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Moxifloxacin is contraindicated in pregnant women due to risk of fetal harm. Animal studies show arthropathy and cartilage damage in immature animals. Human data limited; avoid in all trimesters.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Moxifloxacin is excreted in human milk; M/P ratio unknown. Potential for infant joint damage. Avoid breastfeeding or discontinue drug.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No dose adjustment established. Pregnancy is a contraindication; therefore, use only if no alternative and benefit outweighs risk. No pharmacokinetic studies in pregnancy.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Moxifloxacin is a fourth-generation fluoroquinolone with enhanced activity against Gram-positive bacteria and anaerobes. It achieves high tissue penetration, including into the CSF. Avoid in patients with known QT prolongation or uncorrected hypokalemia due to risk of torsades de pointes. Use with caution in elderly patients and those with renal impairment; no dose adjustment needed for renal impairment but adjust for hepatic impairment (Child-Pugh C). Monitor for signs of tendinitis or tendon rupture, especially in patients over 60, those on corticosteroids, or with kidney, heart, or lung transplants. Administer intravenous infusion over 60 minutes to reduce risk of infusion-related reactions.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Take this medication exactly as prescribed; do not skip doses or stop early even if you feel better.,Contact your doctor immediately if you experience tendon pain, swelling, or rupture (especially in the Achilles tendon), or if you have muscle weakness, joint pain, or difficulty moving.,Avoid excessive sunlight or UV light exposure; use sunscreen and protective clothing as this drug can cause photosensitivity.,This drug may cause dizziness or lightheadedness; do not drive or operate machinery until you know how it affects you.,Drink plenty of fluids to stay hydrated, unless instructed otherwise by your doctor.,Inform your doctor if you have a history of seizures, QT prolongation, heart rhythm problems, or if you are taking antiarrhythmics or other drugs that affect heart rhythm.,Do not take with dairy products, antacids, or supplements containing calcium, magnesium, aluminum, or iron; these can reduce drug absorption. Take moxifloxacin at least 2 hours before or 6 hours after these products.,Report any signs of allergic reaction: rash, hives, difficulty breathing, swelling of face, lips, or throat.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Moxifloxacin, a fluoroquinolone antibiotic, and mefloquine, an antimalarial agent, both prolong the QT interval by inhibiting cardiac potassium channels (specifically hERG channels). When coadministered, there is an additive effect on QTc prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias. This interaction is particularly dangerous in patients with preexisting cardiac conditions, electrolyte imbalances, or bradycardia."
"Moxifloxacin, a fluoroquinolone antibiotic, can decrease the therapeutic efficacy of picosulfuric acid, a stimulant laxative used for bowel cleansing. This interaction likely occurs because moxifloxacin exhibits weak antagonistic activity at the 5-HT4 receptors in the gastrointestinal tract, partially counteracting the prokinetic and secretory effects mediated by picosulfuric acid. Consequently, patients may experience reduced bowel cleansing efficacy, potentially leading to inadequate colonic preparation for colonoscopy and increased risk of missed lesions."
"Dronedarone prolongs the QT interval by blocking multiple cardiac ion channels (primarily IKr). Moxifloxacin also prolongs the QT interval by blocking IKr. Coadministration leads to additive QTc prolongation, increasing the risk of torsades de pointes and ventricular arrhythmias. This risk is particularly elevated in patients with pre-existing electrolyte imbalances, bradycardia, or baseline QT prolongation."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is a Electrolyte that works by Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is: 400 mg intravenously once daily.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is classified as Category A/B. Moxifloxacin is contraindicated in pregnant women due to risk of fetal harm. Animal studies show arthropathy and cartilage damage in immature animals. Human data limited; avoid in . AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.